Canaccord Genuity Maintains a 'Hold' on AngioDynamics (ANGO); Bumping Estimates After Q4 Results
Tweet Send to a FriendGet Alerts ANGO Hot Sheet
Price: $10.71 +0.37%
Rating Summary:
1 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
1 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade ANGO Now!
Canaccord Genuity maintains a 'Hold' on AngioDynamics (NASDAQ: ANGO) price target of $14.50.
Analyst, Jason R. Mills, said, "ANGO management provided clarity and color regarding expected synergies from the Navilyst acquisition, including a strategic roadmap it believes will deliver 10% revenue growth and 15% EPS growth within a few years (i.e. F2015). We think the roadmap is sensible and also think investors can derive some comfort from CEO DeVivo’s strong track record at Rita Medical and Smith & Nephew. However, we maintain our rating as we still harbour some skepticism about expected sales synergies in particular. That said, we would get more constructive with the stock on any pull back to the $10-11 level near-term."
For an analyst ratings summary and ratings history on AngioDynamics click here. For more ratings news on AngioDynamics click here.
Shares of AngioDynamics closed at $11.27 yesterday, with a 52 week range of $10.97-$16.39.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Jason R. Mills, said, "ANGO management provided clarity and color regarding expected synergies from the Navilyst acquisition, including a strategic roadmap it believes will deliver 10% revenue growth and 15% EPS growth within a few years (i.e. F2015). We think the roadmap is sensible and also think investors can derive some comfort from CEO DeVivo’s strong track record at Rita Medical and Smith & Nephew. However, we maintain our rating as we still harbour some skepticism about expected sales synergies in particular. That said, we would get more constructive with the stock on any pull back to the $10-11 level near-term."
For an analyst ratings summary and ratings history on AngioDynamics click here. For more ratings news on AngioDynamics click here.
Shares of AngioDynamics closed at $11.27 yesterday, with a 52 week range of $10.97-$16.39.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Jefferies Bumps Zumiez (ZUMZ) Numbers Up, But Remains on Sidelines
- Pandora (P) Posts 'Strong Quarter' - Needham & Company
- Needham & Company Lifts Numbers on Marvell (MRVL) on Solid Results
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS ViewRelated Entities
Canaccord Genuity
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
